Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $218.0K | $155.0K | $163.0K | $121.0K | $169.0K | $119.0K | $0 | $0 |
| Gross profit | −$218.0K | −$155.0K | −$163.0K | −$121.0K | −$169.0K | −$119.0K | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $18.4M | $17.7M | $11.2M | $17.0M | $18.0M | $4.0M | $14.2M | $11.0M |
| Operating income | −$31.9M | −$30.0M | −$20.5M | −$26.6M | −$27.6M | −$16.3M | −$65.1M | −$50.6M |
| EBITDA | −$31.3M | −$29.8M | −$20.3M | −$26.5M | −$27.5M | −$15.6M | $63.0K | $1.0K |
| Net income | −$31.5M | −$28.8M | −$21.8M | −$25.8M | −$27.0M | −$15.7M | −$62.9M | −$49.9M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -42.81 | -23.46 | -12.52 | -5.80 | -5.95 | -3.42 | -3.51 | -1.96 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $70M | $-1.78 | $-1.78–$-1.78 | 1 |
| 2027 | $128M | $-1.76 | $-1.76–$-1.76 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds ALRN.
No tracked institution reports a position in ALRN as of their last filing.
| Execution date | Ratio |
|---|---|
| 2022-11-11 | 1-for-20reverse |
No one on the platform has traded ALRN yet.
| $45M |
| — |
| KRONKronos Bio, Inc. | $0.88 | +1.49% | $54M | — |
| LUMOLumos Pharma, Inc. | $4.34 | +0.00% | $38M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$RNTX $ALRN This could run to $3+ on high volume.
View on StockTwits ↗$ALRN This could rocket to $3+ any day. $DVLT $PSTV
View on StockTwits ↗$ALRN https://www.prnewswire.com/news-releases/rein-therapeutics-announces-abstract-accepted-for-presentation-at-the-american-thoracic-society-2025-international-conference-302439327.html
View on StockTwits ↗✅ $ALUR was the best premarket trade of the day, jumping from $3.00 to $4.18 after that after-hours PR! 💯💰 ✅ $HOLO running strong on 2024 revenue release news! ✅ $SGLY another 🇨🇳 mover with momentum! ✅ $IBO – a wild 300% runner on NO news! 📈👀 📊 Taking this a step further... The U.S. intragastric balloon market is set to triple in the next 7 years, reaching $144M US & $1.1B globally. ALRN’s share? 30% of that market = serious buyout potential. 💎🔥 💰 Valuation math doesn't lie: $ALRN at $3.58? Market cap = $21.3M Potential buyout? $39.33/share! 🚀📈 💭 "When you have the best product, you sell to the highest bidder." – Remember that. 📌 Don't miss the next big move! Tap in now 👉🔗
View on StockTwits ↗$ALRN what happen no news in alrn or rntx (new name)
View on StockTwits ↗$ALRN $BYSI $OVID 🤫 Shhh… bears trap in action... SQUEEZE -->> CNSP showing signs of life! 🍋 🚀 Rumors flying… PR drop incoming on some BIG moves?! 😏 You know how these moves go - quiet before the storm. Don’t say I didn’t warn ya…🔥 LFG! 🚀🫡
View on StockTwits ↗$ALRN Aileron Therapeutics, Inc. (NASDAQ:ALRN): Shifting Focus to Orphan Pulmonary and Fibrosis Indications https://beyondspx.com/article/aileron-therapeutics-alrn-navigating-the-frontiers-of-orphan-pulmonary-and-fibrosis-treatments
View on StockTwits ↗$ALRN $BYSI $OVID 🚀 MYNZ 🚀 PRs incoming! Spreading the message suggest big news. My bet: FDA re-submission (as hinted by Petra), but any update could be huge. IR presentation points to clinical studies next. MoonDay!
View on StockTwits ↗$ALRN to $RNTX 12:30 PM EST, 01/10/2025 (MT Newswires) -- Rein Therapeutics (ALRN), formerly Aileron Therapeutics, said Friday that it changed names to reflect its focus on developing first-in-class treatments for rare pulmonary and fibrosis diseases. The company's stock will begin trading under the new Nasdaq ticker "RNTX" on Monday, it added. The company also said its key goals for 2025 include initiating a phase 2 trial of LTI-03 for the treatment of idiopathic pulmonary fibrosis in H1.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.